SV2017005474A - Nuevas formas sólidas de desvenlafaxina - Google Patents

Nuevas formas sólidas de desvenlafaxina

Info

Publication number
SV2017005474A
SV2017005474A SV2017005474A SV2017005474A SV2017005474A SV 2017005474 A SV2017005474 A SV 2017005474A SV 2017005474 A SV2017005474 A SV 2017005474A SV 2017005474 A SV2017005474 A SV 2017005474A SV 2017005474 A SV2017005474 A SV 2017005474A
Authority
SV
El Salvador
Prior art keywords
solid forms
new solid
desvenlafaxina
demetilvenlafaxine
reabsortion
Prior art date
Application number
SV2017005474A
Other languages
English (en)
Inventor
Chavez Jorge Guillermo Dominguez
Vasquez Karina Mondragon
Rojas Hugo Morales
Ruiz Dea Herrera
Herbert Höpfl
Martinez Reyna Reyes
Illescas Javier Hernandez
Peláez Juan Pablo Senosiain
Original Assignee
Alparis Sa De Capital Variable
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alparis Sa De Capital Variable filed Critical Alparis Sa De Capital Variable
Publication of SV2017005474A publication Critical patent/SV2017005474A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0018—Evaporation of components of the mixture to be separated
    • B01D9/0022—Evaporation of components of the mixture to be separated by reducing pressure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L9/00—Supporting devices; Holding devices
    • B01L9/02—Laboratory benches or tables; Fittings therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0018—Evaporation of components of the mixture to be separated
    • B01D9/0031—Evaporation of components of the mixture to be separated by heating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/004—Fractional crystallisation; Fractionating or rectifying columns
    • B01D9/0045—Washing of crystals, e.g. in wash columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/02—Crystallisation from solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Clinical Laboratory Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVAS FORMAS SÓLIDAS AMORFAS Y CRISTALINAS DE DESVENLAFAXINA, TAMBIÉN LLAMADO O- DESMETILVENLAFAXINA O DESMETILVENLAFAXINA, Y A SUS SALES, SOLVATOS, HIDRATOS Y POLIMORFOS DE LAS MISMAS, ASÍ COMO A SU USO EN LA PREPARACIÓN DE UNA COMPOSICIÓN FARMACÉUTICA ÚTIL PARA EL TRATAMIENTO DE LA DEPRESIÓN Y/O INHIBIDOR SELECTIVO DE LA REABSORCIÓN DE SEROTONINA Y LA NOREPINEFRINA ASÍ COMO A LOS TRASTORNOS VASOMOTORES ASOCIADOS A LA MENOPAUSIA
SV2017005474A 2016-06-29 2017-06-29 Nuevas formas sólidas de desvenlafaxina SV2017005474A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016008646A MX367362B (es) 2016-06-29 2016-06-29 Nuevas formas solidas de desvenlafaxina.

Publications (1)

Publication Number Publication Date
SV2017005474A true SV2017005474A (es) 2017-10-12

Family

ID=60718150

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005474A SV2017005474A (es) 2016-06-29 2017-06-29 Nuevas formas sólidas de desvenlafaxina

Country Status (7)

Country Link
US (1) US10207982B2 (es)
CA (1) CA2972156C (es)
CO (1) CO2017006492A1 (es)
ES (1) ES2648369B2 (es)
MX (1) MX367362B (es)
PE (1) PE20180025A1 (es)
SV (1) SV2017005474A (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
CA2368083A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
EA011451B1 (ru) 2001-02-12 2009-04-28 Уайт Новая соль сукцинат о-десметилвенлафаксина
US20110046231A1 (en) 2007-10-22 2011-02-24 Actavis Group Ptc Ehf Solid forms of (±)-o-desmethylvenlafaxine salts
EP2085377A1 (en) 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Novel salts of O-desmethyl-venlafaxine
EP2252573A2 (en) * 2008-02-14 2010-11-24 Egis Gyógyszergyár Nyilvánosan Müködö New polymorph and amorphous forms of desvenlafaxine fumarate
IN2008CH00818A (es) * 2008-04-01 2009-10-09 Actavis Group Ptc Ehf
EP2119695A1 (en) 2008-05-16 2009-11-18 Krka Preparation of O-desmethylvenlafaxine salts
US20110112200A1 (en) * 2008-06-16 2011-05-12 Valerie Niddam-Hildesheim Solid states of o-desmethylvenlafaxine salts
CZ301503B6 (cs) 2008-11-27 2010-03-24 Zentiva, A. S. Zpusob prípravy desvenlafaxinu a jeho solí
CZ2009454A3 (cs) 2009-07-15 2010-11-10 Zentiva, K. S. Zpusob prípravy desvenlafaxinu a jeho solí
EP2340818A1 (en) 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of venlafaxine and celecoxib
US8481596B2 (en) * 2011-06-08 2013-07-09 Lupin Limited Polymomorph of desvenlafaxine benzoate

Also Published As

Publication number Publication date
PE20180025A1 (es) 2018-01-09
ES2648369B2 (es) 2018-06-08
US10207982B2 (en) 2019-02-19
CO2017006492A1 (es) 2018-01-05
US20180002273A1 (en) 2018-01-04
CA2972156A1 (en) 2017-12-29
MX2016008646A (es) 2017-12-28
MX367362B (es) 2019-08-16
CA2972156C (en) 2024-06-25
ES2648369A1 (es) 2018-01-02

Similar Documents

Publication Publication Date Title
CL2018003597A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
ECSP19021312A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos
CL2018001790A1 (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748)
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CO2019012957A2 (es) Inhibidores de quinasa y usos de los mismos
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
CO2017001884A2 (es) Polimorfos de selinexor
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
CO2019006687A2 (es) Polimorfos
CO2019006673A2 (es) Polimorfos
CL2019001804A1 (es) Activador de nrf2.
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2016000597A1 (es) Derivados de desoxino jirimicina y sus métodos de uso.
MX386158B (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
BR112016017776A2 (pt) Formas sólidas de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, composições das mesmas e métodos para seu uso
CR20180089A (es) Compuestos útiles para inhibir a ror-gamma-t
MX2016014166A (es) Compuestos de triaminopirimidina utiles para evitar o tratar la malaria.
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
CL2020000190A1 (es) Inhibidores de ror-gamma.
CL2018003872A1 (es) Sales cristalinas del inhibidor de inmunoproteasoma de péptido epoxicetona.
CL2018002149A1 (es) Proceso.